UroGen Pharma Reports Long-Term Data from OLYMPUS Trial of Jelmyto for Upper Tract Urothelial Cancer
Shots:
- UroGen Pharma reported long-term results from the OLYMPUS trial of Jelmyto, FDA-approved for treating low-grade upper tract urothelial cancer (LG-UTUC) in adults
- In the trial, 41/71 patients achieved a complete response with mDoR of 47.8mos. at a median follow-up of 28.1 mos.; 20 patients continued in a long-term follow-up study. Data was published in the Journal of Urology
- The Jelmyto uTRACT Registry is enrolling patients to study real-world UTUC treatment outcomes, with 19 sites activated and 191 patients enrolled as of July 10
Ref: UroGen Pharma | Image: UroGen Pharma
Related News:- UroGen Pharma Reports Real-World Analysis of Jelmyto for Upper Tract Urothelial Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
